Equities Analysts Offer Predictions for KYTX Q1 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Kyverna Therapeutics in a note issued to investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.87) per share for the quarter, down from their prior forecast of ($0.72). HC Wainwright currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.94) EPS and FY2025 earnings at ($3.61) EPS.

Separately, Morgan Stanley lowered their price target on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $18.33.

Kyverna Therapeutics Trading Up 0.5 %

Kyverna Therapeutics stock opened at $1.98 on Monday. The stock has a fifty day moving average price of $2.70 and a 200 day moving average price of $3.95. Kyverna Therapeutics has a 52 week low of $1.86 and a 52 week high of $24.91. The firm has a market capitalization of $85.57 million, a P/E ratio of -0.57 and a beta of 2.57.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.01).

Institutional Investors Weigh In On Kyverna Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in shares of Kyverna Therapeutics by 16.7% during the 4th quarter. Wellington Management Group LLP now owns 274,414 shares of the company’s stock worth $1,026,000 after purchasing an additional 39,291 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Kyverna Therapeutics during the fourth quarter valued at approximately $125,000. Squarepoint Ops LLC purchased a new stake in Kyverna Therapeutics during the fourth quarter worth approximately $43,000. Two Sigma Advisers LP increased its position in shares of Kyverna Therapeutics by 375.1% in the fourth quarter. Two Sigma Advisers LP now owns 80,290 shares of the company’s stock worth $300,000 after acquiring an additional 63,390 shares in the last quarter. Finally, Two Sigma Investments LP lifted its holdings in shares of Kyverna Therapeutics by 47.9% during the 4th quarter. Two Sigma Investments LP now owns 181,654 shares of the company’s stock valued at $679,000 after acquiring an additional 58,800 shares in the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.